|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsor: | University of Saskatchewan |
|---|---|
| Information provided by: | University of Saskatchewan |
| ClinicalTrials.gov Identifier: | NCT00440245 |
Purpose
This study will investigate potential differences in how two puffs of salbutamol protects airway smooth muscle from contracting in people with asthma and chronic obstructive pulmonary disease (COPD).
| Condition | Intervention |
|---|---|
|
Asthma COPD |
Drug: salbutamol |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment, Efficacy Study |
| Official Title: | Bronchoprotection of Salbutamol in Asthma and COPD |
| Estimated Enrollment: | 20 |
| Study Start Date: | February 2007 |
| Estimated Study Completion Date: | December 2010 |
| Estimated Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
salbutamol
There are two groups, asthma and COPD, which are being compared with respect to bronchoprotection from an active treatment (salbutamol).
|
Drug: salbutamol
200 micrograms salbutamol from MDI
|
In asthma, the administration (inhalation) of a selective β2 receptor agonist (e.g. salbutamol), prior to methacholine challenge has been shown to shift the dose response curve to the right and "bronchoprotect" the airway against airway smooth muscle contraction. The extent of β2 receptor agonist bronchoprotection in COPD is unknown.
Airway hyperresponsiveness (AHR) to direct acting agents such as histamine and methacholine is a feature of both asthma and COPD. In asthma, the abnormality leading to AHR is believed to be due to changes in airway smooth muscle (e.g. hypertrophy, hyperplasia, contractile apparatus) whereas in COPD the AHR is likely due to structural or geometric changes.
The investigators hypothesize that the bronchoprotection afforded by salbutamol against methacholine challenge will be greater in asthma than in COPD due to differences in underlying airway abnormalities.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Beth Davis, BSc | 306-966-8290 | beth.davis@usask.ca |
| Canada, Saskatchewan | |
| University of Saskatchewan | Recruiting |
| Saskatoon, Saskatchewan, Canada, S7N 0W8 | |
| Principal Investigator: Donald Cockcroft, MD | |
| Principal Investigator: | Donald Cockcroft, MD | University of Saskatchewan |
More Information
| Responsible Party: | University of Saskatchewan ( Dr. Donald Cockcroft ) |
| Study ID Numbers: | Bio-REB 06-231 |
| Study First Received: | February 22, 2007 |
| Last Updated: | January 26, 2010 |
| ClinicalTrials.gov Identifier: | NCT00440245 History of Changes |
| Health Authority: | Canada: Health Canada |
|
Respiratory System Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Bronchial Diseases Adrenergic Agents Albuterol Physiological Effects of Drugs Reproductive Control Agents Adrenergic Agonists Hypersensitivity Lung Diseases, Obstructive Respiratory Tract Diseases Tocolytic Agents |
Therapeutic Uses Immune System Diseases Adrenergic beta-Agonists Asthma Anti-Asthmatic Agents Pharmacologic Actions Autonomic Agents Lung Diseases Hypersensitivity, Immediate Peripheral Nervous System Agents Bronchodilator Agents Respiratory Hypersensitivity Pulmonary Disease, Chronic Obstructive |
